Skip to content
peptide

CagriSema

emergingInjection

Semaglutide + cagrilintide combo in Phase 3 trials. Strongest weight loss data of any injectable to date, surpassing semaglutide alone through dual appetite/satiety targeting.

Key facts
Classification
Peptide — Next-gen dual semaglutide + amylin analog with strongest weight loss data.
Primary benefits
Fat Loss (10/10) · Gut Health (3/10)
Administration
Injection
Doses studied
2.4 mg semaglutide + 2.4 mg cagrilintide weekly subq. Titrate slowly over several months.
Evidence strength
Emerging
Quick stats
Type
Peptide
Administration
Injection
Studies referenced
0
Stacks with
0 peptides
Goal coverage · CagriSema
🔥 Fat Loss10/10
🫃 Gut Health3/10
FIG.1  Modeled goal coverage from reviewed studies. Score out of 10.
From our network:Cornerstone Peptide